ClinicalTrials.gg
Not yet recruitingNCT07854964Updated Oct 13, 2026

A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal Cancer

An interventional study of Serplulimab and Bevacizumab in Locally Advanced Rectal Cancer, sponsored by Tang-Du Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Tang-Du Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 13, 2026Enrollment updatedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies testing bevacizumab in Rectal Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. Bevacizumab · Rectal Neoplasms.

Planned enrollment
37th of 80
48 · median 45
Started
2026
with 2 others
No phase
5 of 83
2 open now
Primary completion
2030-05
later than 10 of 10 live
Registered
82nd of 83
by date

Among the 83 studies testing bevacizumab in Rectal Neoplasms, this one is the 37th largest by planned enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 82nd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

8 of the 83 studies testing bevacizumab in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing bevacizumab in Rectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to understand the treatment effects of serplulimab combined with XELOX and bevacizumab as neoadjuvant therapy for locally advanced rectal cancer.

  1. What is the effectiveness of this treatment plan for the treatment of locally advanced rectal cancer ?
  2. What is the safety of this treatment for locally advanced rectal cancer ? The type of this study was a single-arm study, and only the patients in the group of Serplulimab combined with XELOX and bevacizumab were observed.

Participates will

  1. The patient underwent four cycles of neoadjuvant therapy with Serplulimab combined with XELOX and bevacizumab (each cycle lasting three weeks).
  2. Preoperative assessment: Imaging evaluation to be conducted within 2-4 weeks after completing neoadjuvant therapy.
  3. Timing of surgery: Perform surgery within 4-6 weeks after completing neoadjuvant therapy.
  4. Surgical method: Choose the appropriate surgical approach (total mesorectal excision, sphincter-preserving or non-sphincter-preserving) based on the tumour location and extent of descent.
  5. Pathological assessment
03

Conditions studied

  • Locally Advanced Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Written must be signed before any trial-related procedures are performed.
  • 2. Male or female, aged ≥18 years and ≤75 years.
  • 3. or pathologically confirmed rectal adenocarcinoma, with confirmed proficient mismatch repair (pMMR) or microsatellite stable (MSS) status; diagnosed as locally advanced rectal cancer according to AJCC 9th edition, with cTNM staging as cT2-4N1-3M0 based on contrast-enhanced CT/MRI, and the lesion assessed as resectable by the investigator.
  • 4. No prior systemic therapy for the current disease, including surgery, anti-tumor radiotherapy/chemotherapy, immunotherapy, etc.
  • 5. performance status 0-1.
  • 6. Expected survival >6 months.
  • 7. Adequate organ function, meeting the following laboratory criteria:

    1. (ANC) ≥1.5×10\^9/L without granulocyte colony-stimulating factor support within the past 14 days;
    2. count ≥100×10\^9/L without blood transfusion within the past 14 days;
    3. >9 g/dL without blood transfusion or erythropoietin use within the past 14 days;
    4. Total ≤1.5× (ULN);
    5. (AST) and alanine aminotransferase (ALT) ≤2.5× ULN;
    6. Serum creatinine ≤1.5× ULN and (calculated using the Cockcroft-Gault formula) ≥60 mL/min;
    7. Adequate coagulation function, defined as (INR) or prothrombin time (PT) ≤1.5× ULN;
    8. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or free T3) and free T4 within the normal range may also be enrolled;
    9. Myocardial enzyme levels within the normal range (isolated laboratory abnormalities deemed clinically insignificant by the investigator's comprehensive judgment are also allowed for enrollment).
  • 8. For female patients who are not or surgically sterile: abstinence or use of effective methods during the treatment period and for at least 7 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • 1.Known squamous cell carcinoma, undifferentiated carcinoma, or other histologic types of colorectal cancer, or adenocarcinoma mixed with other histologic types.
  • 2.Known deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status.
  • 3.Presence of unresectable factors, including unresectability due to tumor-related reasons, presence of surgical , or subject refusal to undergo surgery.
  • 4.Diagnosis of another other than colorectal cancer within 5 years prior to the first dose (excluding adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ).
  • 5.Current participation in interventional clinical research treatment, or receipt of another drug or use of an investigational device within 4 weeks prior to the first dose.
  • 6.Prior receipt of immunotherapy, including (e.g., anti-PD-1/L1 antibodies, anti-CTLA-4 antibodies, anti-TIGIT antibodies, anti-LAG3 antibodies, etc.), immune checkpoint agonists (e.g., ICOS, 0, CD137, GITR, OX40 antibodies, etc.), immune cell therapy, or any other treatment directed at tumor immuno-mechanisms.
  • 7.Severe cardiac disease or conditions, including but not limited to: a confirmed history of heart failure or systolic dysfunction ( \<50%); uncontrolled high-risk arrhythmias, such as atrial tachycardia, resting heart rate >100 bpm, significant ventricular arrhythmias (e.g., ventricular tachycardia), or high-grade atrioventricular block (i.e., Mobitz II second-degree AV block or third-degree AV block).
  • 8.Poorly controlled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg).
  • 9.Inability to swallow, intestinal obstruction, or other factors affecting drug administration and absorption.
  • 10.Known to any component of the study drug regimen; history of immunodeficiency, including positive test, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
  • 11.Female patients who are pregnant, breastfeeding, or of with a positive baseline pregnancy test, or women of childbearing potential who are unwilling to use effective methods throughout the trial and for at least 7 months after the last dose of study treatment.
  • 12.Presence of serious concomitant disease or other confounding conditions that would interfere with planned treatment, or any other condition that, in the investigator's opinion, makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Serplulimab combined with bevacizumab plus XELOX (oxaliplatin + capecitabine) as neoadjuvant therapy for locally advanced rectal cancer

    Drug: Serplulimab · Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • Intravenous infusion, 300 mg, Day 1 of every 3-week cycle, neoadjuvant treatment

  • Intravenous infusion, 7.5 mg/kg, Day 1 of every 3-week cycle, neoadjuvant treatment

  • Intravenous infusion, 130 mg/m², Day 1 of every 3-week cycle, XELOX regimen

  • Oral administration, 1000 mg/m² twice daily, Day 1 to Day 14 of every 3-week cycle, XELOX regimen

06

What researchers measure

Primary outcomes

  1. pCR rate

    The pCR rate and its 95 % confidence interval were calculated

    Time frame: At the time of surgical resection, 4 to 6 weeks after completion of neoadjuvant therapy'

Secondary outcomes

  1. safety analysis

    The incidence of adverse events and its 95 % confidence interval were calculated. Adverse events were summarized according to the classification of system organs.

    Time frame: From first study drug administration through 30 days after surgery

  2. Analysis of objective remission rate

    ORR and its 95 % confidence interval were calculated

    Time frame: Up to 6 weeks after completion of neoadjuvant therapy, prior to surgery

  3. R0 resection rate analysis

    The R0 resection rate and its 95 % confidence interval were calculated

    Time frame: On the day of surgery

  4. Analysis of anal preservation rate

    The anal sphincter preservation rate and its 95 % confidence interval were calculated

    Time frame: On the day of surgery

  5. MMR / MSI status and PD-L1 expression level

    The correlation between biomarkers such as MMR / MSI status and PD-L1 expression level and treatment response was analyzed

    Time frame: Two weeks after operation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2030, 43 months later.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 43 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Oct 2, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
May 15, 2030
CompletionEst.
May 15, 2031
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
37→48
Oct 13, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 13, 2026
    Enrollment 37→48
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854964
Lead sponsor
Tang-Du Hospital
Responsible party
Wang Nan (Chairman of the Department of General Surgery, Chief Physician, Professor, Tang-Du Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
May 15, 2030 (estimated)
Completion
May 15, 2031 (estimated)
Last update
Oct 13, 2026

Study contacts

Nan Wang, Ph.D
Contact
wangnandoc@163.com
02984777431
Nan Wang
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Serplulimab · Bevacizumab

Start the discussion